GlassScriptPhysician profile
Patricia Ross
NPI 1235284886
$3,601.15
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $874 · 2023: $1,092 · 2024: $574 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $977.18 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $531.86 | 2022-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $311.69 | 2021-2025 | Airsupra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $284.50 | 2021-2025 | Lifevest |
| Glaxosmithkline, LLC. | $249.55 | 2023 | |
| Lantheus Medical Imaging, INC. | $221.86 | 2023-2024 | Definity |
| Abbvie INC. | $161.10 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.32 | 2022-2024 | Jardiance |
| Amgen INC. | $139.46 | 2021 | |
| Abbott Laboratories | $137.26 | 2022-2024 | Amplatzer Amulet |
| Lilly USA, LLC | $115.00 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $103.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $94.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $90.23 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $28.16 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.